anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Unlike other vitamins, vitamin D3 is synthesised in skin cells in the body. Vitamin D3 has been known as a bone-related hormone. Recently, however, it has been considered as an immune vitamin. Vitamin D3 deficiency influences the onset of a variety of diseases. Vitamin D3 regulates the production of proinflammatory cytokines such as tumour necrosis factor-α (TNF-α) through binding to vitamin D receptors (VDRs) in immune cells. Since blood levels of vitamin D3 (25-OH-D3) were low in coronavirus disease 2019 (COVID-19) patients, there has been growing interest in the importance of vitamin D3 to maintaining a healthy condition. On the other hand, phytochemicals are compounds derived from plants with over 7000 varieties and have various biological activities. They mainly have health-promoting effects and are classified as terpenoids, carotenoids, flavonoids, etc. Flavonoids are known as the anti-inflammatory compounds that control TNF-α production. Chronic inflammation is induced by the continuous production of TNF-α and is the fundamental cause of diseases like obesity, dyslipidaemia, diabetes, heart and brain diseases, autoimmune diseases, Alzheimer's disease, and cancer. In addition, the ageing process is induced by chronic inflammation. This review explains the cooperative effects of vitamin D3 and phytochemicals in the suppression of inflammatory responses, how it balances the natural immune response, and its link to anti-ageing effects. In addition, vitamin D3 and phytochemicals synergistically contribute to anti-ageing by working with ageing-related genes. Furthermore, prevention of ageing processes induced by the chronic inflammation requires the maintenance of healthy gut microbiota, which is related to daily dietary habits. In this regard, supplementation of vitamin D3 and phytochemicals plays an important role. Recently, the association of the prevention of the non-disease condition called "ME-BYO" with the maintenance of a healthy condition has been an attractive regimen, and the anti-ageing effect discussed here is important for a healthy and long life.
<P>PROBLEM TO BE SOLVED: To provide various kinds of products imparting a high bright feeling to a gel-like composition, enhancing designability thereof and further utilizing the high designability of the gel-like composition.  <P>SOLUTION: The gel-like composition comprising a brightening pigment prepared by coating glass powder with a thin film of titanium dioxide is obtained. The glass powder has ≥80% visible light transmittance. The glass powder is scaly glass. The titanium dioxide is the rutile type. The brightening pigment assumes an interference color. A colorant other than the brightening pigment is contained. The product such as a fragrance agent using the gel-like composition is obtained.  <P>COPYRIGHT: (C)2004,JPO
The invention relates to the field of biological medicine, and provides an anti-NKG 2A monoclonal antibody, wherein the amino acid sequence of HCDR1 is shown as SEQ ID No. 1; the amino acid sequence of HCDR2 is shown in SEQ ID No. 2; the amino acid sequence of HCDR3 is shown in SEQ ID No. 3; the amino acid sequence of LCDR1 is shown as SEQ ID No. 4; the amino acid sequence of LCDR2 is shown in SEQ ID No. 5; the amino acid sequence of LCDR3 is shown in SEQ ID No. 6. The NKG2A inhibitory receptor acting on immune cells is used for relieving the inhibition effect of NKG2A signal channels on the immune cells, enhancing the activities of NK cells, T cells and the like, activating the killing of the NK cells and the like on tumors, and the antibody is a novel check point inhibitor for promoting anti-tumor immunity and is used for preparing medicines for treating cancers or immune diseases.
An electrocardiogram signal classiﬁcation method based on adversarial domain adaptive learning is provided. The features extracted by the multi-scale feature extraction module are highly domain invariant, thus reducing the inter-domain 5 difference. The model trained by the source domain sample can also be well applied in the target domain. After the training of the network is completed, the optimal model is saved, and the new heartbeat samples are input into the saved optimal model to obtain the ﬁnal classiﬁcation result. The use of multi-feature extractors can increase the richness of features and more comprehensively extract the details of the lO electrocardiogram signals. Additionally, the adaptive learning method of the adversarial domain can be employed to improve the phenomenon of different distributions of samples in different domains to obtain domain invariant features between highly summarized source domain samples and the target domain samples. The classiﬁcation model highly suitable for the target domain is trained through these features to improve 15 the classiﬁcation accuracy of cross-domain electrocardiogram signals with different data distributions.
Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
Patients will receive Bilateral accelerated theta-burst stimulation bilaterally for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions.
PURPOSE: Prior studies have shown that treatment intensification for patients presenting with uncontrolled hypertension (HTN) rarely occurs, even during visits to the patient's own primary care physicians (PCPs). In this article, we identified predictors of treatment intensification for uncontrolled HTN.
METHODS: We conducted a cross-sectional study using nationally representative survey data on visits by patients aged 18 or above with uncontrolled HTN, defined as a recorded SBP at least 140 and/or a DBP at least 90 using data from the National Ambulatory Medical Care Survey (NAMCS) 2008-2018. Our outcome is treatment intensification defined as the addition of a new blood pressure medication.
RESULTS: We analyzed 22 559 visits to PCPs where uncontrolled HTN was noted, representing 801 023 786 visits nationally. Among these encounters, 2138 (10.3%) of the visits resulted in treatment intensification. Visits with the patient's own PCP had higher rates of treatment intensification than visits to another PCP (10.8 vs. 5.9%, P  < 0.0001). Visits for patients previously on antihypertensive medications had lower rates of treatment intensification (11% for no medications, 10.4% for one medication, 6.6% for ≥2 medications, P  < 0.0001), but there were no statistically significant differences in rates of intensification for those with relevant comorbidities (9.4% for no chronic conditions, 10.8% for one to two chronic conditions, 8.9% for at least three chronic conditions, P  = 0.12). Multivariable adjusted results were similar to the unadjusted findings.
CONCLUSION: Visits for patients with uncontrolled HTN rarely result in treatment intensification. Substantial opportunity exists to improve management of HTN, particularly for patients on fewer medications or seen by a covering provider.
The invention relates to a toothpaste containing at least one ingredient from the group comprising an abrasive agent, a moistening agent, a swelling agent, a foaming agent, a flavouring substance, a sweetening agent, a conservation agent and fluoride. According to the invention, a whitening agent is added to the toothpaste, said whitening agent containing a photocatalyst which is in particular, in the form of nanoparticles. As a result, the whitening agent contained in the toothpaste can be activated by radiating the wave lengths with light in order to whiten the teeth and to lighten the undesired colour. Optionally, the toothpaste can also be used conventionally for cleaning and caring for the teeth, and without light radiation. Optionally, the toothpaste is used to simply clean the teeth or the contained whitening agent is activated by applying light in order to cosmetically whiten the teeth. The whitening agent contained in the toothpaste can be photoreactive and/or photocatalysed.
<P>PROBLEM TO BE SOLVED: To provide a means for in vivo production of a trans-spliced molecule in a prescribed subset of a cell.  <P>SOLUTION: A pre-trans-splicing molecule (PTM) is a substrate for a trans-splicing reaction between the pre-trans-splicing molecule and a pre-mRNA, which is uniquely expressed in a specific target cell. The in vivo trans-splicing reaction provides a new mRNA which is functional as mRNA or encodes a protein to be expressed in the target cell. The expression product of the mRNA is a protein therapeutically useful for a cell or a host organism, a toxin which causes killing of specific cells, or a new protein not normally present in such cells. Further, the PTMs are genetically engineered for the identification of an exon/intron boundary of a pre-mRNA molecule using an exon tagging method. The PTMs can be designed to result in the production of a chimeric RNA encoding a peptide affinity purification tag.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: Spinal cord ischemia has serious sequelae. The aim of this study is to investigate the effects of resveratrol and caffeic acid phenyl ester (CAPE), a propolis derivative, on spinal cord injury induced by ischemia-reperfusion (IR).
METHODS: In our research, 30 male Wistar albino rats, 200-250 gr, were used. Before the experiment, during a week of the process, the rats were fed with these two agents, and the experimental group rats were exposed to spinal cord IR injury. At the end of the experiment, spinal cord samples were taken from the sacrificed rats. Bax, p53, nNOS, and Beclin-1 immunoreactivity moreover TUNEL (+) cells were evaluated with immunohistochemically in the IR-induced damaged rats.
RESULTS: It has been clearly determined that the TUNEL (+) apoptotic cell number and immunopositive cells of nNOS, Beclin-1, p53, Bax were raised in the IR group. However, these increments partially were restored in the resveratrol and CAPE-fed rats with IR-induced injury.
CONCLUSION: In light of our data, resveratrol, and CAPE could be beneficial in spinal cord IR injury. Although both agents provide beneficial effects, it can be said that CAPE is partially more effective in spinal cord injury caused by IR.
BACKGROUND AND AIM: Colorectal cancer is a prevalent malignancy worldwide, and right hemicolectomy is a common surgical procedure for its treatment. However, postoperative incisional infections remain a significant complication, leading to prolonged hospital stays, increased healthcare costs, and patient discomfort. Therefore, this study aims to utilize machine learning models, including random forest, support vector machine, deep learning models, and traditional logistic regression, to predict factors associated with incisional infection following right hemicolectomy for colon cancer.
METHODS: Clinical data were collected from 322 patients undergoing right hemicolectomy for colon cancer, including demographic information, preoperative chemotherapy status, body mass index (BMI), operative time, and other relevant variables. These data are divided into training and testing sets in a ratio of 7:3. Machine learning models, including random forest, support vector machine, and deep learning, were trained using the training set and evaluated using the testing set.
RESULTS: The deep learning model exhibited the highest performance in predicting incisional infection, followed by random forest and logistic regression models. Specifically, the deep learning model demonstrated higher area under the receiver operating characteristic curve (ROC-AUC) and F1 score compared to other models. These findings suggest the efficacy of machine learning models in predicting risk factors for incisional infection following right hemicolectomy for colon cancer.
CONCLUSIONS: Machine learning models, particularly deep learning models, offer a promising approach for predicting the risk of incisional infection following right hemicolectomy for colon cancer. These models can provide valuable decision support for clinicians, facilitating personalized treatment strategies and improving patient outcomes.
Type 2 Diabetes - Adults (see Table 5)

One six-month, open-label, active-controlled study was conducted to compare the safety and efficacy of Insulin Aspart to regular human insulin in patients with type 2 diabetes (Table 5). 

The mean age of the trial population was 56.6 years and mean duration of diabetes was 12.7 years. Sixty-three percent were male. Seventy-six percent were Caucasian, 9% were Black and 15% were Other. The mean BMI was approximately 29.7 kg/m2. 

Insulin Aspart was administered by subcutaneous injection immediately prior to meals and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily doses. Changes in HbA1c were comparable for the two treatment regimens.

Table 5. Subcutaneous Insulin Aspart Administration in Type 2 Diabetes (6 months; n=176)

*Values are Mean ± SD
The investigators will measure and compare the immediate effect of the presence of the dog, on days with low stress and high stress, using non-invasive measures of the physiological response, diary notes, and data on activity and sleep pattern The latter will also be collected for the service dogs. The investigators will apply a cross-sectional design. The participants will be divided into two groups based on whether they own a certified service dog (treatment group) or are on a waitlist for a service dog (control group).

The experimental period will consist of a 14-day period. In the preceding week the participants receive a visit, where they will be given instructions to fill in a diary, how to collect and store saliva samples, and use equipment for data collection. In the diary they record their daily activities and any situation perceived to be stressful during the experimental period. In the experimental period, the participants will wear an accelerometer. Every second day, the particpants will wear equipment measuring their heart rate.
PURPOSE: A composition containing dried powder or its extract of chub mackerel is provided to ensure blood pressure reduction, treat and prevent hypertension. CONSTITUTION: A pharmaceutical composition for preventing and treating hypertension contains dried powder or its extract of chub mackerel fraction as an active ingredient. The dried powder or its extract is contained in 0.1-50 weight% based on total weight of the pharmaceutical composition. A method for producing the dried powder of chub mackerel fraction comprises: a step of washing the chub mackerel to remove foreign materials and salt; a step of cutting into whole body of the fish, skin, head, fin, bone, cartilage, muscle, eye and gill; and a step of performing freeze-drying or sun drying. The extract of chub mackerel fraction is obtained through pulverizing, pressing or extracting with a mixer or extracting with water, alcohol or spirit solvent. A functional health food for preventing and treating hypertension contains dried powder or extract of chub mackerel fraction as an active ingredient. The health food is used in the form of tablet, capsule, pill or liquid.
The present invention relates to medicine which is a dual-layer slow releasing tablet of benproperine phosphate. The dual-layer slow releasing tablet comprises the raw material of benproperine phosphate slow releasing medicine and the raw material of normal releasing medicine, and is prepared into a dual-layer tablet by double pressing. The proportion of the raw materials of the main medicine of the benproperine phosphate in the raw material of the normal releasing medicine and the raw material of the slow releasing medicine is 13.2 to 34.6 milligrams to 39.6 to 66 milligrams. A layer of normal releasing tablet is added on the basis of releasing tablets of the benproperine phosphate to cause the dual-layer slow releasing tablet simultaneously to have the advantages of fast taking effect in common preparations, and long and stable medicine effect of slow releasing preparations. The dual-layer slow releasing tablet can achieve the quick release of normal releasing part medicine in vivo. After the dual-layer slow releasing tablet quickly reaches the effective blood and medicine concentration, the slow releasing parts are slowly released to continuously maintain the effects, such as stable and effective blood and medicine concentration, etc.
Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. 

Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin (see WARNINGS and ADVERSE REACTIONS sections). 

Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs, however, most cases occur at doses ≥60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. 

The incidence of the syndrome has not been defined.
OBJECTIVE: Screening of feature genes involved in cytokine release syndrome (CRS) from the coronavirus disease 19 (COVID-19).
METHODS: The data sets related to COVID-19 were retrieved using Gene Expression Omnibus (GEO) database, the differentially expressed genes (DEGs) related to CRS were analyzed with R software and Venn diagram, and the biological processes and signaling pathways involved in DEGs were analyzed with GO and KEGG enrichment. Core genes were screened using Betweenness and MCC algorithms. GSE164805 and GSE171110 dataset were used to verify the expression level of core genes. Immunoinfiltration analysis was performed by ssGSEA algorithm in the GSVA package. The DrugBank database was used to analyze the feature genes for potential therapeutic drugs.
RESULTS: This study obtained 6950 DEGs, of which 971 corresponded with CRS disease genes (common genes). GO and KEGG enrichment showed that multiple biological processes and signaling pathways associated with common genes were closely related to the inflammatory response. Furthermore, the analysis revealed that transcription factors that regulate these common genes are also involved in inflammatory response. Betweenness and MCC algorithms were used for common gene screening, yielding seven key genes. GSE164805 and GSE171110 dataset validation revealed significant differences between the COVID-19 and normal controls in four core genes (feature genes), namely IL6R, TLR4, TLR2, and IFNG. The upregulated IL6R, TLR4, and TLR2 genes were mainly involved in the Toll-like receptor signaling pathway of the inflammatory pathway, while the downregulated IFNG genes primarily participated in the necroptosis and JAK-STAT signaling pathways. Moreover, immune infiltration analysis indicated that higher expression of these genes was associated with immune cell infiltration that mediates inflammatory response. In addition, potential therapeutic drugs for these four feature genes were identified via the DrugBank database.
CONCLUSION: IL6R, TLR4, TLR2, and IFNG may be potential pathogenic genes and therapeutic targets for the CRS associated with COVID-19.
There was a case of intentional overdose with ZURZUVAE reported during premarketing clinical trials. The patient took 330 mg (6.5 times the maximum recommended dose) of ZURZUVAE and was reported to be in an altered state of consciousness. The event resolved the next day, following treatment with intravenous fluids. 

Overdosage with ZURZUVAE may result in excessive CNS depressant effects such as somnolence and disturbance in consciousness. There is no specific antidote for ZURZUVAE overdosage. 

Consider contacting the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
The involvement of kidney, perirenal fat, and ureter is a rare variant of inguinal hernia. We report a case of a 78-year-old man presenting with typical clinical signs of acute appendicitis. Ultrasonography and CT scan revealed ptosis of the right kidney with a major part of the perirenal capsule involved in a large right sided inguinal hernia with acute obstruction of the ureter and urostasis. Acute surgery was performed, involving resection of perirenal fat, liberation, resection, and neoimplantation of the ureter, and hernioplasty. The postoperative period was uneventful. This case illustrates diagnostic unpredictability of acute appendicitis as well as anatomic variety of inguinal hernias.
Harness is set up in families' homes for one month. Caregivers re asked to use the harness with their infant for 30 min/day, 5 times a week.
Pathological breakdown of membrane lipids through excessive lipid peroxidation (LPO) was first described in the mid-20th century and is now recognized as a form of regulated cell death, dubbed ferroptosis. Accumulating evidence unveils how metabolic regulation restrains peroxidation of phospholipids within cellular membranes, thereby impeding ferroptosis execution. Unleashing these metabolic breaks is currently therapeutically explored to sensitize cancers to ferroptosis inducing anti-cancer therapies. Reversely, these natural ferroptotic defense mechanisms can fail resulting in pathological conditions or diseases such as ischemia-reperfusion injury, multi-organ dysfunction, stroke, infarction, or neurodegenerative diseases. This minireview outlines current ferroptosis-inducing anti-cancer strategies and highlights the detection as well as the therapeutic targeting of ferroptosis in preclinical experimental settings. Herein, we also briefly summarize observations related to LPO, iron and redox deregulation in patients that might hint towards ferroptosis as a contributing factor.
The invention discloses a traditional Chinese medicine composition for treating dysmenorrhoea. The traditional Chinese medicine composition comprises, by weight, 10-15 parts of motherwort, 5-8 parts of pilose asiabell root, 3-5 parts of cyperus rotundus, 7-8 parts of lithospermum, 10-12 parts of prepared rehmannia root, 8-10 parts of fructus psoraleae, 8-10 parts of Chinese angelica, 10-15 parts of walnut kernel, 5-10 parts of ligusticum wallichii, 4-5 parts of safflower, 6-8 parts of red peony root, 2-5 parts of cockscomb, 6-8 parts of poria cocos, 5-10 parts of root of three-nerved spicebush, 10-12 parts of rhizoma corydalis, 30-50 parts of radix astragali, 5-8 parts of peony root bark, 2-5 parts of kekuioilplant leaf, 1-3 parts of vermiculite schist seu and 5-10 parts of licorice root. The above traditional Chinese medicine ingredients cooperate. Ligusticum wallichii, walnut kernel, red peony root, cockscomb, safflower, rhizoma corydalis and peony root bark have effects of promoting blood circulation to remove blood stasis and regulating qi to alleviate pain. The root of three-nerved spicebush and fructus psoraleae have effects of warming kidney and regulating qi. The prepared rehmannia root has effects of nourishing yin and blood. The radix astragali, pilose asiabell root, poria cocos and licorice root have effects of invigorating spleen and tonifying qi. Through synergism of the above traditional Chinese medicines, the traditional Chinese medicine composition has effects of coursing liver and rectifying qi, promoting blood circulation to remove blood stasis, and freeing channels and relieving pain.